Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_assertion type Assertion NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_head.
- NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_assertion description "[Despite the high incidence of revertant mosaicism (35%) in patients with the genetic skin disease epidermolysis bullosa (EB) due to correcting mutations in the genes COL17A1 and LAMB3, revertant mosaicism has not been described for COL7A1 until recently.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_provenance.
- NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_assertion evidence source_evidence_literature NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_provenance.
- NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_assertion SIO_000772 20574443 NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_provenance.
- NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_assertion wasDerivedFrom befree-20140225 NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_provenance.
- NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_assertion wasGeneratedBy ECO_0000203 NP643294.RArtoSIoGI1-2g62dr9BT6qqatSQYdtBdjH41Re-MlDQU130_provenance.